Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Canertinib + MRTX-1133 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Canertinib | CI-1033 | EGFR Inhibitor (Pan) 63 HER inhibitor (Pan) 6 | Canertinib (CI-1033) is a pan-ERBB inhibitor that inhibits EGFR, ERBB2 (HER2), ERBB3 (HER3), and ERBB4 (HER4) signaling, which may result in decreased tumor growth (PMID: 11706399, PMID: 17342332, PMID: 30425998). | |
| MRTX-1133 | MRTX1133|MRTX 1133 | KRAS G12D Inhibitor 25 | MRTX-1133 selectively inhibits KRAS G12D, which results in decreased downstream signaling and potentially leads to reduced tumor growth (PMID: 34889605). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|